Recent 8-K filings for JAGX
Highest-materiality recent filing
Jaguar Health receives Nasdaq delisting notice for insufficient publicly held shares after reverse split
- Post 1-for-35 reverse stock split on April 30, 2026, publicly held shares are ~401,226, below 500,000 minimum.
- Nasdaq Staff notified company on May 1, 2026 of additional deficiency under Listing Rule 5550(a)(4).
-
Jaguar Health regains Nasdaq Bid Price compliance; monitoring until May 2027
Formal notice from Nasdaq on May 26, 2026: Jaguar complies with Bid Price Rule (closing bid ≥$1/sh).
-
Issued 54,222 common shares to Streeterville in exchange for 7.96 shares of Series Q Preferred Stock.
-
Jaguar Health Q1 revenue up 816% to $20.3M on $19M license deal; net loss narrows to $7.0M
Total revenue $20.3M (816% YoY increase) driven by $19.1M license revenue from Woodward/Future Pak deal.
-
Jaguar Health exchanges $22.7M in royalty interests for Series Q Preferred Stock
Uptown Capital: $12.5M royalty reduction for 500 Series Q shares.
-
Jaguar Health gets Nasdaq extension to May 18 for bid-price compliance; delisting risk remains
Received Nasdaq Staff notice on May 1, 2026 for non-compliance with 500,000 publicly held shares requirement.
-
Post 1-for-35 reverse stock split on April 30, 2026, publicly held shares are ~401,226, below 500,000 minimum.
-
Jaguar Health cures Nasdaq publicly held shares deficiency via warrant exercises after reverse split
Received Nasdaq notice on May 1, 2026 for non-compliance with minimum 500,000 publicly held shares after 1-for-35 reverse split on April 30.
-
Jaguar Health granted Nasdaq extension to May 15, 2026; announces 1-for-35 reverse stock split
Nasdaq Panel grants extension until May 15, 2026 to demonstrate compliance with $1.00 minimum bid price rule.
-
Jaguar Health regains Nasdaq equity compliance after $27M in capital events
Stockholders' deficit was $18.7M at Dec 31, 2025, below Nasdaq's $2.5M minimum.
-
Net revenue FY2025 $11.5M (-1.5% YoY); Q4 2025 net revenue $3.2M (+5% QoQ, -8% YoY).
-
Jaguar Health postpones royalty payments, extends notes, terminates 48,211 warrants
Royalty payment start postponed to July 1, 2026; Uptown amount reduced to $11,125,282.54, Streeterville to $12,428,782.20.
-
Jaguar Health receives Nasdaq delisting notice for bid price; plans to appeal
Nasdaq notice on March 5, 2026: bid price below $1.00 for 30 consecutive business days.
-
Jaguar Health declared a one-time special stock dividend of Series O Preferred Stock on February 18, 2026.
-
Jaguar Health issues ~11.8M pre-funded warrants to reduce $2.04M in royalties and preferred stock
Reduced $1.19M Iliad royalty and $0.85M Streeterville royalty by issuing 1.55M and 1.11M pre-funded warrants.
-
Exclusive license to Future Pak for Mytesi (HIV/AIDS diarrhea) and Canalevia-CA1 (chemotherapy-induced diarrhea in dogs) in U.S.
-
Jaguar Health swaps 91 Series M Preferred shares for 440K common shares and 1.6M pre-funded warrants
On Dec 9, exchanged 75 Series M Preferred for 400K common shares and warrant for 1,304,545 shares at $0.001.
-
JAGX stockholders approve three proposals; crofelemer MVID trial shows up to 37% PS reduction
Stockholders approved proposal to issue shares upon exchange/redemption of Series N Preferred Stock (1,032,716 For, 73,065 Against).
-
Jaguar Health amends $36M royalty obligations, extends debt, exchanges preferred for common
Royalty Interest amendments set minimum monthly payment of $750,000 per $12M royalty from April 1, 2026.
-
Jaguar Health issues $10.81M secured note to Streeterville Capital; $8M held as collateral
Net proceeds of $10M after $800K OID and $10K transaction expenses; interest 8% p.a., maturity 36 months.
-
Jaguar Health raises $1M via PIPE: 161,583 shares + 479,442 pre-funded warrants at $1.56/share
Issued 161,583 common shares and 479,442 pre-funded warrants to Brown Stone Capital at $1.56/share (warrant price $1.5599); total proceeds $1M.
-
Jaguar Health raises $2.38M via Series N Perpetual Preferred Stock PIPE
Issued ~951 Series N Preferred shares at $2,500 stated value each for aggregate proceeds of $2.38M.
-
Jaguar Health cuts royalty debt by $6.5M, issues Series M preferred to Iliad and Streeterville
Issued 170 shares of Series M Preferred to Iliad for $4.25M reduction in October 2020 royalty interest.
-
Jaguar Health reduces royalty debt by $1.016M via equity exchanges; Q1 results released
Issued 60,000 shares to Iliad for $466,200 reduction in October 2020 royalty interest.
-
Crofelemer reduces TPN up to 27% in MVID and 12.5% in SBS-IF in proof-of-concept trial
Initial POC data shows novel liquid crofelemer reduced parenteral support in MVID and SBS-IF patients by up to 27% and 12.5% respectively.
-
Jaguar Health extends note maturity to July 2025, reduces royalty balance by $1.09M via stock
Issued 1,290,000 shares to a royalty holder in exchange for $1,094,952 reduction in outstanding royalty balance.
-
Jaguar Health 2024 revenue $11.7M, up 20% YoY; net loss narrows to $38.5M
2024 net revenue of ~$11.7M (prescription+non-prescription+license) increased ~20% from $9.8M in 2023.
-
Jaguar Health raises $3.45M via convertible notes; CEO & insiders participate
$3.448M aggregate principal convertible notes at 6% interest, 3-month maturity, convertible into common stock at ~$5.54/share.
-
Jaguar Health announces 1-for-25 reverse stock split effective March 24 to meet Nasdaq compliance
Reverse split at 1-for-25 ratio, effective March 24, 2025 at 12:01 am ET.
-
Jaguar Health adopts 1-year rights plan after receiving acquisition interest
Board adopted limited-duration rights plan on Feb 26, 2025; expires Feb 26, 2026.
-
Jaguar Health extends note maturity to July 2025, issues shares to reduce royalty liability
Note amendment with Streeterville Capital extends maturity of $6.22M secured promissory note to July 20, 2025.
Earnings & guidance
Materiality & sentiment trend
Max materiality 0.85 · Median 0.60 · Most common event other_material